Cargando…
Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer
BACKGROUND: Survival and drug response are two highly emphasized clinical outcomes in cancer research that directs the prognosis of a cancer patient. Here, we have proposed a late multi omics integrative framework that robustly quantifies survival and drug response for breast cancer patients with a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992339/ https://www.ncbi.nlm.nih.gov/pubmed/33761889 http://dx.doi.org/10.1186/s12864-021-07524-2 |
_version_ | 1783669353721364480 |
---|---|
author | Malik, Vidhi Kalakoti, Yogesh Sundar, Durai |
author_facet | Malik, Vidhi Kalakoti, Yogesh Sundar, Durai |
author_sort | Malik, Vidhi |
collection | PubMed |
description | BACKGROUND: Survival and drug response are two highly emphasized clinical outcomes in cancer research that directs the prognosis of a cancer patient. Here, we have proposed a late multi omics integrative framework that robustly quantifies survival and drug response for breast cancer patients with a focus on the relative predictive ability of available omics datatypes. Neighborhood component analysis (NCA), a supervised feature selection algorithm selected relevant features from multi-omics datasets retrieved from The Cancer Genome Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC) databases. A Neural network framework, fed with NCA selected features, was used to develop survival and drug response prediction models for breast cancer patients. The drug response framework used regression and unsupervised clustering (K-means) to segregate samples into responders and non-responders based on their predicted IC50 values (Z-score). RESULTS: The survival prediction framework was highly effective in categorizing patients into risk subtypes with an accuracy of 94%. Compared to single-omics and early integration approaches, our drug response prediction models performed significantly better and were able to predict IC50 values (Z-score) with a mean square error (MSE) of 1.154 and an overall regression value of 0.92, showing a linear relationship between predicted and actual IC50 values. CONCLUSION: The proposed omics integration strategy provides an effective way of extracting critical information from diverse omics data types enabling estimation of prognostic indicators. Such integrative models with high predictive power would have a significant impact and utility in precision oncology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-021-07524-2. |
format | Online Article Text |
id | pubmed-7992339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79923392021-03-25 Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer Malik, Vidhi Kalakoti, Yogesh Sundar, Durai BMC Genomics Research Article BACKGROUND: Survival and drug response are two highly emphasized clinical outcomes in cancer research that directs the prognosis of a cancer patient. Here, we have proposed a late multi omics integrative framework that robustly quantifies survival and drug response for breast cancer patients with a focus on the relative predictive ability of available omics datatypes. Neighborhood component analysis (NCA), a supervised feature selection algorithm selected relevant features from multi-omics datasets retrieved from The Cancer Genome Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC) databases. A Neural network framework, fed with NCA selected features, was used to develop survival and drug response prediction models for breast cancer patients. The drug response framework used regression and unsupervised clustering (K-means) to segregate samples into responders and non-responders based on their predicted IC50 values (Z-score). RESULTS: The survival prediction framework was highly effective in categorizing patients into risk subtypes with an accuracy of 94%. Compared to single-omics and early integration approaches, our drug response prediction models performed significantly better and were able to predict IC50 values (Z-score) with a mean square error (MSE) of 1.154 and an overall regression value of 0.92, showing a linear relationship between predicted and actual IC50 values. CONCLUSION: The proposed omics integration strategy provides an effective way of extracting critical information from diverse omics data types enabling estimation of prognostic indicators. Such integrative models with high predictive power would have a significant impact and utility in precision oncology. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-021-07524-2. BioMed Central 2021-03-24 /pmc/articles/PMC7992339/ /pubmed/33761889 http://dx.doi.org/10.1186/s12864-021-07524-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Malik, Vidhi Kalakoti, Yogesh Sundar, Durai Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
title | Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
title_full | Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
title_fullStr | Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
title_full_unstemmed | Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
title_short | Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
title_sort | deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992339/ https://www.ncbi.nlm.nih.gov/pubmed/33761889 http://dx.doi.org/10.1186/s12864-021-07524-2 |
work_keys_str_mv | AT malikvidhi deeplearningassistedmultiomicsintegrationforsurvivalanddrugresponsepredictioninbreastcancer AT kalakotiyogesh deeplearningassistedmultiomicsintegrationforsurvivalanddrugresponsepredictioninbreastcancer AT sundardurai deeplearningassistedmultiomicsintegrationforsurvivalanddrugresponsepredictioninbreastcancer |